Who are NVX-CoV2705 Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CCP, BNT162b2 Pfizer-BioNTech/Comirnaty, mRNA-1273 Variant-containing Formulation, Ad26.COV2.S vaccine, Novavax recombinant protein vaccine, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nvx-cov2705-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

NVX-CoV2705 Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NVX-CoV2705 Vaccine (NVX-CoV2705 Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein subunit vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein subunit vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

NVX-CoV2705 Vaccine (NVX-CoV2705 Vaccine) — Novavax. NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NVX-CoV2705 Vaccine TARGET	NVX-CoV2705 Vaccine	Novavax	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein subunit vaccine class)

Novavax · 2 drugs in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class
EuBiologics Co.,Ltd · 1 drug in this class
Pfizer · 1 drug in this class
Serum Institute of India Pvt. Ltd. · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NVX-CoV2705 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/nvx-cov2705-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab